Navigation Links
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
Date:1/25/2008

s and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the Company's ability to successfully complete the clinical trials required for it to file a new drug application for CPP-109, its ability to complete such trials on a timely basis within the budgets established for such trials, whether the Company's trials, which are being conducted in the U.S. under FDA good clinical practice guidelines, will evidence that CPP-109 is safe and effective for the treatment of cocaine addiction and methamphetamine addiction, the Company's ability to protect its intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2006 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 that the Company has previously filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... EAST BRUNSWICK, N.J., Feb. 17, 2012  Savient Pharmaceuticals, Inc. (NASDAQ: ... Vice President and Chief Financial Officer of Savient will present ... February 28, 2012 at 8:30 AM Eastern Time.  The conference ... York City. A live webcast of the presentation ...
... (Nasdaq: ENDP ) today announced that Mark Gottlieb, ... the J.P. Morgan Annual Global High Yield & Leveraged Finance ... The conference will be held at the Loews Hotel in ... archive of the presentation will be available on the company,s ...
Cached Medicine Technology:Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 2
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... Air pollution could be putting patients with heart disease at ... , A study by the University of Edinburgh and Ume ... blood vessel function in men who have previously experienced a ... Heart Foundation and published in the New England Journal of ...
... Armed with satellite imagery, field samples, human Lyme disease ... from the University of New Hampshire, the New Hampshire ... sector will conduct work on the ecology and risk ... states in an effort to eventually identify "hot spots" ...
... Quilt a ,Beautiful Symbol, NEW YORK, Sept. 12 ... Bolds, as "a homemaker." Doing,everything the old-fashioned way, Aylene ... a clothes line, washing and drying her dishes,by hand, ... aroma from the kitchen met you at the front ...
... Where do personal,trainers go to gain more knowledge? Well, ... sciences relating to fitness from conferences, trade,associations and certifying ... list. PersonalTrainerTV.com is a new membership web site for,fitness ... from leading,experts in the industry. According to its ...
... 2007 Approximately 30% of Canadians suffer daily from ... the intensity, but all chronic pain is debilitating and ... Lamb, a clinician nurse at the Pain Centre of ... Shir, the Director of the Centre, shows that methadone ...
... PORTLAND, Maine, Sept. 12 JHA has released the ... Survey. This leading,benchmarking survey reports group Long Term Disability ... premium results for the first,half of the year. The ... of the top twenty carriers, as ranked by inforce ...
Cached Medicine News:Health News:Diesel exhaust may increase risk in patients with heart disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 2Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 3Health News:UNH, state health agency, private industry and NASA to tackle Lyme disease 4Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 2Health News:Alzheimer's Foundation of America to Display Quilt to Remember in Los Angeles 3Health News:Methadone and systematic follow-up: the best solution for managing chronic pain 2Health News:JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: